Find a Doctor

AN
Areas of Expertise

Aziz Nazha

Cleveland Clinic Foundation
Hematology, Oncology, Internal Medicine
Male
Practicing approx. 14 years

Bio

Aziz Nazha is a Hematologist and an Oncologist in Cleveland, Ohio. He has been an author on 99 peer reviewed articles and participated in 4 clinical trials in the past 15 years. He is licensed to treat patients in TX and OH.

Areas of Expertise

Contact

9500 Euclid Ave
Cleveland, OH 44195, US

Latest Research

Latest Advance
Study
  • Condition: Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML)
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib
  • Number of Patients: 0
  • Published —
A phase I trial of the second-generation proteasome inhibitor ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).
Latest Advance
Study
  • Condition: Myelodysplastic Syndromes (MDS)
  • Journal: Blood advances
  • Treatment Used: Immunosuppressive Therapy (IST)
  • Number of Patients: 207
  • Published —
This study examined outcomes associated with immunosuppressive therapy (IST) and predictors of benefit in a large international cohort of patients with myelodysplastic syndromes (MDS).

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 68
  • Start Date: July 15, 2019
A Phase Ib Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 29
  • Start Date: July 3, 2019
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 500
  • Start Date: November 12, 2018
Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613® (Devimistat) in Combination With High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) Therapy and Control Sub-groups: Combination of Mitoxantrone, Etoposide and Cytarabine (MEC) and Combination of Fludarabine, Cytarabine, and Filgrastim (FLAG) in Older Patients (≥ 50 Years) With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 28
  • Start Date: January 29, 2018
Targeting TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia (AML) With Azacitidine and Ascorbic Acid

All Publications
View All

Publication
Conference
  • Sponsor: American Society of Hematology (ASH)
  • Event Name: American Society of Hematology Annual Meeting and Exposition 2020
  • Published —
Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)
Publication
Conference
  • Sponsor: American Society of Hematology (ASH)
  • Event Name: American Society of Hematology Annual Meeting and Exposition 2020
  • Published —
A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Contact

9500 Euclid Ave
Cleveland, OH 44195, US

Affiliations

  • Cleveland Clinic

Credentials

  • Licenses
    Internal Medicine in TX
  • Board Certifications
    Hematology/oncology

Insurance

Contact them to find out if they accept your insurance plan.